Search

The MEDICIS facility is a unique facility located at CERN dedicated to the production of non-conventional radionuclides for research and development in imaging, diagnostics and radiation therapy. It exploits in a Class A work sector, a dedicated isotope separator beam line, a target irradiation station at the 1.4 GeV Proton Synchroton Booster (PSB) and receives activated targets from external institutes during CERN Long Shut-Downs. The target is heated up at high temperatures to allow for the diffusion and effusion of the atoms out of the target that are subsequently ionized. The ions are accelerated and sent through an off-line mass separator. The radionuclide of interest is extracted through mass separation and implanted into a thin metallic collection foil. After collection, the batch is prepared to be dispatched to a research center. In the near-future, the radiochemistry process will also be performed in MEDICIS. Since its commissioning in December 2017, the facility has provided novel radionuclides such as Tb-149, Tb-155, Tm-165, Er-169 and Yb-175 with high specific activity, some for the first time, to European research institutes part of the collaboration., Proceedings of the 11th International Particle Accelerator Conference, IPAC2020, Caen, France

HPV vaccination is expected to reduce the incidence of cervical cancer. The greatest and the earliest health gains will be ensured by high vaccine coverage among all susceptible people. The high costs and the risk of a reduced cost/effectiveness ratio in sexually active girls still represent the main obstacles for a more widespread use of HPV vaccination in many countries. Data on the rate, risk factors, and HPV types in sexually active women could provide information for the evaluation of vaccination policies extended to broader age cohorts. Sexually active women aged 13-26 years enrolled in an Italian cohort study were screened for cervical HPV infections; HPV-DNA positive samples were genotyped by InnoLipa HPV Genotyping Extra or by RFLP genotype analysis. Among the 796 women meeting the inclusion criteria, 10.80% (95% CI 8.65-12.96) were HPV-DNA infected. Age >18 years, lifetime sexual partners >1, and history of STIs were associated to higher risk of HPV infection in the multivariable models adjusted for age, lifetime sexual partners, and time of sexual exposure. The global prevalence of the four HPV vaccine-types was 3.02% (95% CI 1.83-4.20) and the cumulative probability of infection from at least one vaccine-type was 12.82% in 26-years-old women and 0.78% in 18-years-old women. Our data confirm most of the previously reported findings on the risk factors for HPV infections. The low prevalence of the HPV vaccine-types found may be useful for the evaluation of the cost/efficacy and the cost/effectiveness of broader immunization programs beyond the 12-years-old cohort. © 2014 Landes Bioscience.

Obiettivi: Dalle analisi dei dati degli studi precedenti effettuati in Sicilia sono emerse diverse indicazioni, per cui è stata avviata un’indagine in Sicilia nel 2013 , grazie ad un finanziamento della LILT nazionale, intesa a: valutare la situazione immunologica ed ematochimica e la sieroprevalenza in persone a stretto contatto con i malati (parente di 1 grado o marito/moglie) o parenti affetti dalla stessa patologia; indagare alcuni fattori di rischio con un questionario;effettuare il follow-up dei malati ogni 6-12-18-24 mesi ; individuare un Centro di Riferimento in Sicilia per la diagnosi e cura di questo tumore raro. Materiali e Metodi: Sono stati arruolati 24 Casi (21M/3F) e 27 Controlli familiari (9M/18F), residenti in Sicilia e solo un caso di sesso maschile residente in Calabria. La casistica non include 3 casi maschi perché arruolati per la seconda volta al follow-up ; inoltre 1 caso M e relativo controllo (moglie) è stato escluso in quanto affetto da altro tipo di Sarcoma. I controlli sono stati familiari consanguinei e/o non consanguinei ( moglie, marito, genero ecc..) di casi in cura presso le Università di Catania e Messina oppure già arruolati negli studi precedenti dalla LILT di Ragusa, alcuni dei quali deceduti. Risultati: Dal confronto tra Controlli HHV8 positivi (n°11) vs. Controlli HHV8 negativi (n°16) non sono state individuate differenze significative a eta’, sesso, livello d’istruzione, occupazione e varie esposizione ambientali (età : >64 vs